Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES

BACKGROUND: Data are limited regarding the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir regimen (PrOD) upon the rate of liver fibrosis progression and incidence of cirrhosis and hepatic decompensation after treatment for HCV. METHODS: Within ERCHIVES (Electronically Retrieved Cohort of HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Tracey, Yan, Peng, Kort, Jens, Butt, Adeel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632046/
http://dx.doi.org/10.1093/ofid/ofx163.379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632046/
http://dx.doi.org/10.1093/ofid/ofx163.379

Ejemplares similares